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Abstract: Gene expression proﬁ  les from DNA microarrays can provide molecular signatures that improve tumor classiﬁ  cation, 
prognosis, and treatment options. While much of this work has focused on isolation of RNA from the resected tumor, 
fewer studies have utilized RNA from ﬁ  ne needle aspirates (FNA). In this pilot study we examined whether the gene 
signatures obtained from FNA samples would correlate with signatures taken from the resected tumor. Based on NSCLC 
gene expression proﬁ  les obtained from eleven sets of FNA and tumor samples we obtained a high concordance of FNA 
proﬁ  les matching their matched tumor sample. These results suggest that FNA samples may provide informative gene 
expression signatures regarding the potential aggressiveness of non-small-cell lung carcinomas.
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Introduction
Lung cancer is the most common cause of cancer death in the U.S. (Socinski, Schell et al. 2002). 
Non-small cell lung carcinomas (NSCLC) account for 70–80% of lung malignancy (Fu, Zhu et al. 
1999). The majority of patients with NSCLC present with advanced stage III or IV disease. Despite 
advances in the diagnosis, staging, and treatment of NSCLC, the overall 5-year survival rate remains 
poor (Sause, Kolesar et al. 2000). 
In an effort to improve the treatment of NSCLC, molecular “ﬁ  ngerprinting” using DNA microarrays, 
has been undertaken (Nacht, Dracheva et al. 2001). This technology has led to the identiﬁ  cation of gene 
expression patterns that are improving NSCLC tumor classiﬁ  cation, biomarker identiﬁ  cation, prog-
nosis/outcome predictions, understanding of altered molecular pathways, and targeted therapies 
(Petty, Nicolson et al. 2004). 
Classical gene expression proﬁ  ling (GEP) requires a tissue sample from the tumor, RNA extraction, 
and DNA hybridization to determine which genes are expressed in a given tumor. While GEP has proven 
useful in lung cancer patients, samples have generally been derived from surgical specimens in patients 
with resectable disease (Beer, Kardia et al. 2002). Unfortunately, most patients with NSCLC have 
unresectable disease. Further, in the future, even patients with resectable disease may beneﬁ  t from 
neoadjuvant therapy prior to resection. In both of these situations, GEP data derived from needle biopsy 
would be potentially beneﬁ  cial.
The few studies examining GEP from ﬁ  ne needle aspirations (FNAs) of lung cancer have been disap-
pointing, in part due to RNA degradation (Lim, Aggarwal et al. 2003). The purpose of this pilot study 
was to compare GEP proﬁ  les from needle biopsies to GEP proﬁ  les from the resected tumor in the same 
cohort of patients.
Materials and Methods
Sample collection
The study was approved by the Institutional Review Boards of   Wright State University School of 
Medicine and the Dayton VA Medical Center on Dec. 17, 2004. After informed consent, a total of 14 254
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patients with suspected resectable non-small cell 
lung cancer (NSCLC) entered the study between 
Oct. 4, 2005 and May 16, 2006. Two of the 14 
patients ultimately were found not to have NSCLC 
on ﬁ  nal pathologic analysis (one lymphoma, one 
metastatic renal cell carcinoma), resulting in a 
study of 12 patients with NSCLC. One additional 
needle sample (adenocarcinoma) had to be 
excluded from the analysis due to poor array data 
resulting in a ﬁ  nal 11 sets of tumor and needle gene 
expression proﬁ  les (Table 1).
Patient treatment
Patients underwent an extensive preoperative 
history, physical examination, and radiologic and 
laboratory testing. Studies included pulmonary 
function testing, arterial blood gas analysis, cardiac 
stress testing, CT scans of the chest, positron emis-
sion tomography (PET) scans, bronchoscopy, and 
mediastinoscopy in an effort to preoperatively 
stage the patient and determine perioperative risk. 
Several of these indices can be found in Table 2.
At operation, all patients underwent bronchos-
copy to determine proper position of double-lumen 
endotracheal tubes. Prophylactic antibiotics were 
given. Patients either underwent video thoracosopy 
or posterolateral thoracotomy for initial wedge 
resection or biopsy of the lesion. During the 
operation, just prior to resection of the lung mass, 
a true cut needle biopsy with an 18G detachable 
biopsy system (Boston Scientiﬁ  c, Natick, MA) was 
performed either thorascopically or via thora-
cotomy. Specimens were immediately placed in 
RNALater solution (Ambion, Austin, TX). An 
additional needle biopsy specimen was sent for 
frozen section. Once malignancy was conﬁ  rmed, 
the lesion was resected via wedge resection, lobec-
tomy, or pneumonectomy depending on the size 
and location of the tumor and the health of the 
patient. Additional large specimens from the 
resected (or open biopsied) parent tumor were also 
placed in RNALater solution. Following resection, 
a systematic mediastinal lymph node sampling was 
performed. Immediately postoperatively, needle 
biopsy and resected specimens were transported 
to the Wright State Univ. Center for Genomics 
Research (WSU-CGR).
Patients were extubated in the operating room 
or recovery room. Pain management postopera-
tively included an epidural catheter infusion of 
fentanyl and bupivicaine. Complications were 
deﬁ  ned according to a previous publication from 
this Department (Pezzella, Adebonojo et al. 2000). 
Charlson comorbidity scores were calculated 
(Birim, Zuydendorp et al. 2003). Statistical anal-
ysis was performed using the NCSS/PASS 2000 
(NCSS Statistical Software, Kaysville, UT) and 
InStat (GraphPad, San Diego, CA) software 
programs. Survivorship was determined using the 
Kaplan-Meier product limit method. 
RNA isolation
Tumor and needle biopsy samples were pelleted, 
RNAlater removed and tissues stored at –80 
oC 
until the samples were processed. Frozen tissues 
were placed in liquid nitrogen and then transferred 
to a tissue pulverizer pre-frozen overnight at –20 
oC. The pulverized tissue was resuspended in Trizol 
reagent and total RNA isolated following manu-
facturer’s recommendations (Invitrogen, Gaithers-
burg, MD). An aliquot of the eluted RNA was 
analyzed using a RNA Nano 6000 chip on an 
Table 1. Tumor Histology and RNA Quantiﬁ  cations.
Code  Tumor Type  RNA Yields (T/N; µg)  RIN Values (T/N)
1S Squamous  1589/10.8  NA
1L Large  Cell  414/5.8  NA
2S Squamous  233/17.3  8.9/9.2
3S Squamous  232/14.4  7.2/9.2
4S Squamous  79/21  8.8/9.4
5S Squamous  369/22  8.3/9.7
1As Adenosquamous  34/0.7  9.2/8.9
2As Adenosquamous  154/12.5  7.4/8.7
6S Squamous  131/14.6  9.2/8.9
1Ac Adenocarcinoma  36.5/2.6  7.3/7.5
7S Squamous  211.5/29.5  9.4/8.4255
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Agilent Bioanalyzer (Agilent, Santa Clara, CA). 
For each sample, generation of biotinylated cRNA 
began with six hundred nanograms of total RNA 
employing a two-step Affymetrix labeling kit as 
described by the manufacturer (Affymetrix, Santa 
Clara, CA). 
DNA microarray
Fragmented biotinylated cRNA probe was hybrid-
ized to an Affymetrix GeneChip HGU133 Plus 2 
containing over 47,000 putative gene transcripts. 
The GeneChips were incubated for 16 hours 
at 42 
oC prior to washing, staining and scanning 
following Affymetrix protocols.
Data analysis
Affymetrix GeneChip CHP ﬁ  les, scaled to 150, 
were loaded into GeneSpring 7.3 for data analysis. 
For studies examining all 22 GeneChips (needle 
and tumor) a genelist consisting of genes present 
(P) in at least 1 out of 22 GeneChips was created 
(42093 genes). When determining if the gene 
expression proﬁ  les of needle biopsies mirrored 
their tumor biopsy match a condition tree was run 
using a Pearson correlation and average linkage 
using the 42093 genes that were present in one of 
the 22 GeneChips used in the analysis linkage. 
Identical results were obtained when the analysis 
was run using only genes present in all 22 samples 
(data not shown). Bootstrapping (1000 iterations) 
was performed to derive a conﬁ  dence value for 
each branch of the condition tree. All FNA:Tumor 
matches had 100% conﬁ  dence values. 
Results
Since most patients with non-small cell lung carci-
noma are diagnosed with advanced disease, resec-
tion may not be an option. In this study we wanted 
to examine whether needle biopsies would provide 
gene expression profiles that matched those 
obtained from resected tumors. While a prior study 
suggested ﬁ  ne needle aspirates (FNA) produced 
expression proﬁ  les that matched their respective 
tumor samples; only 40% of the FNA samples 
provided RNA of sufﬁ  cient quality for analysis 
(Lim, Aggarwal et al. 2003). In this study we 
recruited 14 patients over a six-month period from 
which 12 patients were diagnosed with NSCLC. 
Table 1 contains the information regarding these 
patients’ tumor type, yield of RNA, and quality of 
the RNA based on RIN analysis using a RNA nano 
6000 chip (Agilent Bioanalyzer). As expected we 
recovered only a fraction of RNA from needle 
biopsies compared to tumor biopsies (0.7–26%, 
Table 2. Patient Characteristics.
Variable Result
Age (years)  61.9 ± 3.1
Sex (males/females)  11/0
Pack years smoking  64.1 ± 12.4
Current smoker  7/11 (64%)
Charlson comorbidity index  1.8 ± 0.3
Symptoms 9/11  (82%)
Dyspnea 6/11  (55%)
Weight loss  2/11 (17%)
ECOG performance status  0.8 ± 0.2
Karnofsky performance status (%)  87 ± 3
PO2 (mm Hg)  82.4 ± 5.1
PCO2 (mm Hg)  39.0 ± 1.0
FEV1 (liters)  2.39 ± 0.2
FEV1% predicted  69.8 ± 5.9
DLCO% predicted  49.7 ± 4.7
Operation
 Lobectomy  7611  (55%)
  Wedge resection  3/11 (27%)
 Pneumonectomy  1/11  (9%)
  Biopsy only  1/11 (9%)
Tumor size (cm)  4.6 ± 0.6
Stage
 I  7/11  (64%)
 II  3/11  (27%)
 III  1/11  (9%)
Complications 2/11  (18%)
Perioperative death  0/11 (0%)
Chemotherapy 10/11  (91%)
Radiation 4/11  (36%)
Figure 1. Kaplan- Meier survival plot. Survival of the 11 patients in 
this study. Only two individuals have died during follow-up, consistent 
with the observation that most of these tumors were early stage 
NSCLCs (Table 1).256
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Table 1). Nevertheless, the quality of the RNA as 
determined using the RNA integrity (RIN) values 
(Schroeder, Mueller et al. 2006) was above average 
for both types of samples. 
The majority of patients were smokers with 
moderately severe emphysema by pulmonary 
function testing (Table 2). With the exception of 
their pulmonary disease, patients were in 
otherwise reasonable health as judged by high 
performance status and low comorbidity indices. 
Most patients had early stage disease, and had 
good long term survival, consistent with a study 
of “resectable” lung cancer (Figure 1). The 
predominance of squamous cell histology is due 
to predominantly male, heavy smoking patients 
in a VA population as previously reported (Paull, 
Updyke et al. 2005).
To ascertain whether the FNA samples contained 
a sufﬁ  cient amount of tumor sample to provide a 
gene expression proﬁ  le indicative of the tumor 
sample, the gene expression proﬁ  les from the 11 
needle aspirates were compared to the 11 tumor 
biopsies using a Pearson correlation coefﬁ  cient. 
As shown in Figure 2, nine of the eleven needle 
samples (81.8%) were most like their tumor match 
(Figure 2). Only FNAs 3S and 4S, both from 
squamous cell carcinomas, failed to correlate with 
their tumor samples. Through the use of bootstrap-
Figure 2. Condition Tree of the 22 GeneChip proﬁ  les compared based on tissue type. The 11 sets of gene expression proﬁ  les were compared 
using the Pearson correlation with average linkage. The tree details the relationship of the 22 proﬁ  les with the gene signals (red-high expres-
sion, green-low expression) shown for each of the 42093 genes that were analyzed. Of the 11 sets of proﬁ  les, 9 of them showed that the FNA 
proﬁ  le was most similar to the proﬁ  le from its matching tumor. Colorbar represents how the color changes relate to relative expression.257
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ping we were able to demonstrate that these 
matches (FNA:Tumor) could not occur by 
chance.
In addition to using this unbiased approach, 
we also mined the microarray data using genes 
known to be altered in NSCLC. Parathyroid 
hormone like hormone (PTHLH) has been 
previously identified as being induced in 
NSCLCs (Nishigaki, Ohsaki et al. 1999; Hiraki, 
Ueoka et al. 2002). After grouping the needle 
and tumor biopsy array data by tumor type we 
conﬁ  rmed that PTHLH was indeed induced, most 
strongly in the squamous cell carcinoma tissues 
(Figure 3A). Another potential target gene 
PLUNC was originally identiﬁ  ed by differential 
display as being detected in 80% of NSCLC 
tumors that were lymph node positive (Iwao, 
Watanabe et al. 2001). Although the Affymetrix 
GeneChip only possesses a single probe set 
targeting PLUNC, we found the gene expressed 
Figure 3. Examination of PTHLH and PLUNC relative expression across various histological NSCLCs. The 11 needle and 11 tumor proﬁ  les 
were grouped into one of four histological subtypes and gene expression levels averaged among each group. (A) PTHLH expression is high 
in both the needle and tumor squamous samples (n = 7) and lowest in the adenocarcinoma (n = 1) and adenosquamous samples (n = 2). 
All four probesets for PTHLH show similar expression patterns. (B) PLUNC probe set shows that highest expression in the adenocarcinoma 
samples (n = 2) and is also detected in the squamous cell needle and tumor samples (n = 7). The expression of PLUNC appears higher in 
needle samples compared to tumor samples in the adenocarcinoma and large cell proﬁ  le. This may result from the fact that the needle bi-
opsies contain some normal tissue and PLUNC is found expressed in normal lung tissue (Bingle, Cross et al. 2005). Colorbar represents 
how the color changes relate to relative expression.258
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in all tumors examined with elevated expression 
in the adenocarcinoma (Figure 3B). Taken 
together these results from the unsupervised 
hierarchical clustering approach (Figure 2) and 
examination of genes known to be altered in 
NSCLC (Figure 3) suggest that the FNA gene 
proﬁ  les were a good representation of the tumor 
gene expression proﬁ  le. 
Discussion
The goal of this pilot project was to determine 
whether high quality RNA could be isolated from 
ﬁ  ne needle aspirates taken from patients with non 
small cell lung carcinomas and if so how well the 
gene expression profiles obtained from these 
specimens represented the gene expression proﬁ  les 
from the actual tumors. Unlike a previous study 
(Lim, Aggarwal et al. 2003), we obtained high 
quality RNA from FNAs (Table 1) and even though 
the yields for several samples were rather low, were 
able to employ the Affymetrix Two-Step cDNA 
labeling procedure to produce a sufﬁ  cient amount 
of biotinylated cRNA to label HGU133 Plus 2 
GeneChips. Based on a statistical comparison of 
the GEPs from the FNAs and tumor samples over 
80% of the FNAs GEPs most closely correlated 
with their matching tumor sample. It is possible 
that the GEPs from the two FNAs which did not 
match their respective tumor sample may have 
resulted from a higher than acceptable amount of 
non-tumor RNA within the FNA. Future studies to 
correlate matches with the percentage of tumor 
tissue within a FNA will provide an important 
criteria to enable clinicians to assess whether a 
given FNA is suitable for microarray analysis. The 
finding of concordance between GEP profiles 
obtained from needle biopsies and the parent tumor 
for patients with non-small cell lung cancer is 
signiﬁ  cant. Up to this point, only patients with 
early stage, resectable lung cancer were in a posi-
tion to be aided by GEP data (Beer, Kardia et al. 
2002). Unfortunately, patients with early stage lung 
cancer make up only the minority of all lung cancer 
patients. Needle biopsy derived GEPs would allow 
patients with unresectable lung cancer to derive 
potential beneﬁ  ts; for example, prognostic infor-
mation, chemotherapy selection, or targeted thera-
pies (Petty, Nicolson et al. 2004). In addition, it is 
likely that in the future, even patients with resect-
able lung cancer will undergo neoadjuvant chemo-
therapy prior to resection (Patel, Blum et al. 2004). 
Needle biopsy GEPs could conceivably play a role 
in such a setting. These results suggest that 
obtaining microarray results from FNAs is feasible, 
provides data that is representative of the primary 
tumor and may provide gene signatures of early 
stage NSCLCs that can be used to predict 
outcomes.
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